Want to see KLRS full AI Analyst Report?
KLRS Stock Chart & Stats
$4.20
-$0.15(-4.02%)
At close: 4:00 PM EDT
$4.20
-$0.15(-4.02%)
Day’s Range― - ―
52-Week Range$3.03 - $11.88
Previous Close$3.5
Volume71.67K
Average Volume (3M)80.81K
Market Cap
$85.61M
Enterprise Value$4.72
Total Cash (Recent Filing)$93.54M
Total Debt (Recent Filing)$1.40M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 18, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding23,804,981
10 Day Avg. Volume52,346
30 Day Avg. Volume80,805
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-2.98
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.50Price Target Upside269.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
TH103 Clinical DifferentiationEarly efficacy, safety and pharmacokinetic findings suggest TH103 may provide durable retinal benefit and less frequent dosing than existing therapies. If confirmed in later trials, this could support meaningful differentiation and improve the program’s competitive positioning.
Pipeline AdvancementProgression into a Phase 1b/2 study demonstrates operational execution beyond initial proof-of-concept. Continued patient dosing and manufacturing readiness create a path toward dose selection and later-stage development, supporting the value of the lead program.
Low Financial LeverageMinimal debt reduces interest and refinancing pressure while the company funds clinical development. Although the balance sheet is shrinking, low leverage preserves flexibility and avoids the added obligations that can constrain highly indebted development-stage biotechs.
Bears Say
No Commercial RevenueKalaris has no commercial revenue base to offset research, development and operating costs. Its financial outlook therefore remains dependent on clinical success, future financing or partnerships, leaving the business exposed until a product can be commercialized.
Persistent Cash BurnSustained negative operating and free cash flow indicates that clinical progress requires continuing external funding. A slightly worsening burn rate can increase dilution or financing risk and may limit development flexibility if capital markets or partnership access weakens.
Shrinking Equity BaseThe steady reduction in equity reflects cumulative losses and cash consumption, weakening the company’s financial cushion. This erosion raises the importance of successful financing or clinical milestones and reduces resilience against delays, trial setbacks or higher development costs.
Kalaris Therapeutics News
KLRS FAQ
What was Kalaris Therapeutics’s price range in the past 12 months?
Kalaris Therapeutics lowest stock price was $3.03 and its highest was $11.88 in the past 12 months.
What is Kalaris Therapeutics’s market cap?
Kalaris Therapeutics’s market cap is $85.61M.
When is Kalaris Therapeutics’s upcoming earnings report date?
Kalaris Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 76 days.
How were Kalaris Therapeutics’s earnings last quarter?
Kalaris Therapeutics released its earnings results on Aug 11, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.495 by $0.015.
Is Kalaris Therapeutics overvalued?
According to Wall Street analysts Kalaris Therapeutics’s price is currently Undervalued.
Does Kalaris Therapeutics pay dividends?
Kalaris Therapeutics does not currently pay dividends.
What is Kalaris Therapeutics’s EPS estimate?
Kalaris Therapeutics’s EPS estimate is -0.52.
How many shares outstanding does Kalaris Therapeutics have?
Kalaris Therapeutics has 23,804,981 shares outstanding.
What happened to Kalaris Therapeutics’s price movement after its last earnings report?
Kalaris Therapeutics reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.495. Following the earnings report the stock price went up 0.761%.
Which hedge fund is a major shareholder of Kalaris Therapeutics?
Currently, no hedge funds are holding shares in KLRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kalaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (269.05% Upside)
$15.50 (269.05% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 9.2%
Last 30 Days ▼ 9.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kalaris Therapeutics
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
KLRS Stock 12 Month Forecast
Average Price Target
$15.50
▲(269.05% Upside)
Technical Analysis
Coherus Biosciences
―
Nektar Therapeutics
―
Cellectis SA
―
Seres Therapeutics
―
Kodiak Sciences
―
Ownership Overview
54.44% Insiders
1.98% Mutual Funds
4.37% Other Institutional Investors
38.07% Public Companies and
Individual Investors